Experienced in Acute Lymphoblastic Leukemia (ALL)

Maria-elisabeth C. Goebeler

Oberdürrbacher Str. 6, 
Wuerzburg, BY, DE 
Experienced in Acute Lymphoblastic Leukemia (ALL)
Oberdürrbacher Str. 6, 
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Maria-elisabeth Goebeler practices in Wuerzburg, Germany. Goebeler is rated as an Experienced expert by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Their top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Leukemia, and Non-Hodgkin Lymphoma.

Their clinical research consists of co-authoring 30 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Acute Lymphoblastic Leukemia (ALL).

Locations

Oberdürrbacher Str. 6, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The GDFATHER-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The GDFATHER-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).
Enrollment Status: Active_not_recruiting
Publish Date: August 09, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

30 Total Publications

Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.
Journal: JCO precision oncology
Published: August 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Goebeler's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile